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This study aimed at examining the early eﬀects of hyperbaric oxygen therapy (HBOT) on inducible nitric oxide synthase (iNOS)
activity/expression in lymphocytes of type 1 diabetes mellitus (T1DM) patients. A group of 19 patients (mean age: 63± 2.1) with
T1DM and with the peripheral arterial disease were included in this study. Patients were exposed to 10 sessions of HBOT in the
duration of 1 h to 100% oxygen inhalation at 2.4 ATA. Blood samples were collected for the plasma C-reactive protein (CRP),
plasma free fatty acid (FFA), serum nitrite/nitrate, and serum arginase activity measurements. Expression of iNOS and
phosphorylation of p65 subunit of nuclear factor-κB (NFκB-p65), extracellular-regulated kinases 1/2 (ERK1/2), and protein kinase
B (Akt) were examined in lymphocyte lysates by Western blot. After exposure to HBOT, plasma CRP and FFA were signiﬁcantly
decreased (p < 0 001). Protein expression of iNOS and serum nitrite/nitrate levels were decreased (p < 0 01), while serum arginase
activity was increased (p < 0 05) versus before exposure to HBOT. Increased phosphorylation of NFκB-p65 at Ser536
(p < 0 05) and decreased level of NFκB-p65 protein (p < 0 001) in lymphocytes of T1DM patients were observed after
HBOT. Decreased phosphorylation of ERK1/2 (p < 0 05) and Akt (p < 0 05) was detected after HBOT. Our results indicate
that exposure to HBO decreased iNOS activity/expression via decreasing phosphorylation of ERK1/2 and Akt followed by
decreased activity of NFκB.
1. Introduction
Diabetes mellitus (DM) type 1 (T1DM) is a multifactorial
autoimmune disease associated with signiﬁcant morbidity
and mortality related to microvascular and macrovascular
complications [1, 2]. T1DM is associated with abnormal
synthesis of nitric oxide (NO) via activation of inducible
NO synthase (iNOS) [3, 4], and an increased level of
iNOS enzyme is associated with DM-related vascular com-
plications [5–8]. The iNOS gene expression is stimulated
through activation of transcription factors, such as nuclear
factor-κB (NFκB). Furthermore, induction of iNOS is
mediated via stimulation of NFκB, by diﬀerent stimuli
including extracellular-regulated kinases (ERK1/2) and pro-
tein kinase B (Akt) [9, 10].
Systemic hyperbaric oxygen (HBO) therapy (HBOT) has
been proposed as a medical treatment for DM patients with
the developed peripheral arterial disease. HBOT is deﬁned
as therapeutic inhalation of 100% oxygen in the elevated
pressure controlled conditions, which induces micro- and
macrovascular hemodynamic changes [11]. An increase
in oxygen arterial partial pressure in hyperbaric conditions
promotes better solubility of plasma oxygen. This further
results in the preservation of vitality of tissues, reversibly
damaged by atherosclerosis-induced ischemia, simulta-
neously with microcirculation restoration [12]. Exposure
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to HBO decreases iNOS activity/expression followed by
reduction of NO generation, which implies that this may be
mechanisms responsible for the anti-inﬂammatory eﬀect of
HBOT [13, 14]. However, the exact molecular mechanism
by which HBOT reduces inﬂammation remains still unclear.
We hypothesized that HBO aﬀects iNOS regulation
through inhibition of the NFκB activation, by a mechanism
that involves phosphorylation of ERK1/2 and Akt. The aim
of this prospective pilot study was twofold: (1) to investigate
the early eﬀects of HBOT on iNOS activity/expression and
(2) to investigate the involvement of Akt and ERK1/2 in the
regulation of iNOS activity/expression, in T1DM patients
exposed to HBO.
2. Material and Methods
2.1. Chemicals and Reagents. Lymphocyte separation media
(LSM), Lymphosep, was obtained from BioWest S.A.S
(Nuaillé, France). Protease inhibitor (Complete, Ultra, Mini,
EDTA-free) and phosphatase inhibitor (PhosStop) cocktails
were obtained from Roche (Mannheim, Germany). Luminol
and p-coumaric acid were obtained from Sigma-Aldrich
Corporation (St. Louis, MO, USA). The commercially
available kit for determination of total cholesterol Beckman
enzymatic reagent kit was purchased from Beckman Coulter
(Brea, CA, USA). The nitrate/nitrite colourimetric assay kit
was purchased from Cayman Chemical (Ann Arbor, MI,
USA). For measuring the activity of arginase, we used
L-arginine monohydrochloride obtained from Kemika
(Zagreb, Croatia) and alpha-isonitrosopropiophenone
(ISPF) obtained from Sigma-Aldrich Corporation (St. Louis,
MO, USA). The polyclonal rabbit anti-iNOS and
anti-NFκB-p65, monoclonal mouse anti-actin antibody, sec-
ondary anti-mouse, and anti-rabbit IgG horseradish
peroxidase-linked antibodies were obtained from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA). The following
antibodies were obtained from Cell Signaling Technology
Inc. (Danvers, MA, US): anti-phospho-NFκB-p65 (Ser536),
anti-phospho-ERK1/2 (Thr202/Tyr204), anti-total ERK1/2,
anti-phospho-Akt (Ser473), and anti-total Akt antibodies.
The enhanced chemiluminescent reagent was obtained from
Amersham, GE Healthcare (Buckinghamshire, UK).
2.2. Subjects and Methods. After obtaining the Ethical
Committee of Zemun Clinical Hospital approval and written
informed consent, 19 type 1 DM (T1DM) patients with no
obvious DM ulcers, inﬂammatory redness on lower extremi-
ties, and contraindications for HBOT were included in this
prospective pilot study during 2017, in Zemun Clinical
Hospital, Zemun, Serbia. The study inclusion criterion was
the presence of T1DM with the peripheral arterial disease.
A total of 10 sessions of HBOT were applied as one session
per day, for two weeks, in the duration of 1 h of 100% oxygen
inhalation at 2.4ATA. The demographic properties and
medical history of all patients were recorded on the ﬁrst
visit, including gender, type of diabetes, current diabetes
condition, hypertension, and other concomitant therapy
of study interest (aspirin, statins, ﬁbrates, antiplatelet ther-
apy, angiotensin-converting enzyme inhibitors, angiotensin
receptor blockers, calcium-channel blockers, and beta
blockers). The peripheral arterial disease was conﬁrmed by
the standard questionnaire. Blood samples were collected,
and lymphocytes were isolated and stored at −20°C. Half of
the collected blood was transferred to EDTA-containing
vacutainer tubes, incubated on ice for one hour, and subse-
quently centrifuged for 15min at 2000×g. Obtained superna-
tants (plasma) were stored at −20°C before analysis. Serums
were isolated by incubation of blood at room temperature
for 30min without anticoagulants, followed by 15min centri-
fugation at 1800×g. Serumswere stored at−20°Cuntil further
biochemical analysis. Glycosylated hemoglobin A1c (HbA1c),
C-reactive protein (CRP), free fatty acids (FFA), nitrite/ni-
trate levels, and arginase activity were measured before and
after completion of HBOT. Complete blood count, total cho-
lesterol, and triglyceride (TG) were measured before HBOT.
2.3. Measurement of Serum HbA1c Levels. The measurement
of HbA1c was carried out using an immunological method
with an antibody to the beta chain of HbA1c on Roche cobas
c 501 analyzer (Roche Diagnostics, Indianapolis, IN, USA).
The HbA1c results are expressed as a percentage of glycosyl-
ated hemoglobin (%).
2.4. Measurement of Plasma TG and Total Cholesterol
Concentration. The concentration of TG was measured using
a commercially available kit according to the manufacturer’s
guidelines using a Roche cobas c 501 analyzer (Roche Diag-
nostics, Indianapolis, IN, USA). The concentration of total
cholesterol was measured by standardized enzymatic colour
test using Beckman Coulter Olympus AU400 analyzer (Brea,
CA, USA) [15]. Total cholesterol and TG concentrations
were expressed as mmol/L.
2.5. Measurement of Plasma CRP and FFA Concentrations.
The concentration of CRP in the plasma was measured by
the immunoturbidimetric method using a commercially
available kit (system reagent for the quantitative determina-
tion of CRP in human plasma), following manufacturer
guidelines, on Roche cobas c 501 analyzer (Roche Diagnos-
tics, Indianapolis, IN, USA). CRP concentrations were
expressed in mg/L and presented as % of CRP before HBOT.
The FFA concentration was measured in the plasma con-
taining EDTA, using a modiﬁed version of the Duncombe
method [16]. The principle of the method is that extracted
FFA in chloroform, in the presence of an appropriate reagent
(aqueous solution of Cu(NO3)2× 3H2O with triethanola-
mine, pH7.8), forms salts of copper, which in contact with
diethyldithiocarbamate builds a yellow complex compound
with a maximum absorbance at 436nm [15]. The concentra-
tions of FFA were expressed in mmol/L and presented as % of
FFA before HBOT.
2.6. Measurement of Serum Nitrite/Nitrate Concentration
and Arginase Activity. The concentration of the serum nitrite
and nitrate was measured by using a nitrate/nitrite colouri-
metric assay kit (Cayman Chemical, Ann Arbor, MI, USA)
according to the manufacturer’s protocol [15]. The concen-
trations of nitrite/nitrate were expressed in mmol/L and
presented as % of nitrite/nitrate before HBOT.
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Arginase activity was measured spectrophotometrically
in serum, according to the method of Corraliza et al. [17].
Arginase is the enzyme that converts L-arginine to urea and
L-ornithine; thereby, the principle of this method is based
on measurement of the amount of generated urea which is
directly proportional to arginase activity. Brieﬂy, aliquots of
serum were incubated for 10min at 55°C in complete assay
mixture lacking arginine. The reaction was initiated by
addition of L-arginine, and incubation was continued at
37°C for 1 h. The reaction was terminated by heating at
100°C for 45min. Values of arginase activity were expressed
in nmol/min/mg of proteins and presented as % of arginase
activity before HBOT.
2.7. Isolation of Lymphocytes from Peripheral Blood. The hep-
arinized whole blood samples from each patient were used
for the isolation of lymphocytes with LSM, according to the
method of Boyum [18]. The lymphocytes forming a layer
directly above the LSM were isolated and washed twice with
phosphate-buﬀered saline. Each wash was followed by centri-
fugation at 1200×g for 10min. Finally, the supernatant was
removed and stored at −70°C for further analysis.
2.8. Isolation of Proteins from Lymphocytes. Whole cell
extracts were prepared by suspending cell pellets in ice-cold
buﬀer for protein isolation (150mM sodium chloride (NaCl),
20mM tris(hydroxymethyl)aminomethane (TRIS), 2mM
ethylenediaminetetraacetic acid (EDTA), 2mM dithiothrei-
tol (DTT), 1% nonionic detergent Triton X-100, and 10%
glycerol) containing phosphatase and protease inhibitor
cocktails. Lymphocytes were lysed by rotation at +4°C for a
period of 1 h. Lysed samples were then centrifuged for
30min at 14000×g at +4°C. Protein concentration was deter-
mined by the Lowry method [19]. The supernatants were
stored at −70°C for further analysis.
2.9. SDS-PAGE and Western Blotting. The lysate proteins
(40μg/lane) were separated by 10% or 12% SDS-PAGE
and transferred to PVDF membranes as previously
described [20]. Membranes were blocked with 5%
bovine serum albumin and probed with the following anti-
bodies: anti-iNOS, NFκB-p65 (Ser536), anti-NFκB-p65,
anti-phospho-Akt (Ser473), anti-total Akt, anti-pho-
spho-ERK1/2 (Thr202/Tyr204), and anti-total ERK1/2. The
membranes were washed and incubated with the appropriate
secondary HRP-conjugated antibody and after that used for
detection with the enhanced chemiluminescent reagent.
Anti-actin monoclonal antibodies were used as a loading
control. The obtained signals were quantiﬁed using ImageJ
software (NIH, USA).
2.10. Statistical Analysis. Values are expressed as means
± SEM. SPSS 18.0 for Windows (SPSS Inc., Chicago, IL,
USA) was used for all statistical calculations. Analysis of data
was evaluated using two-tailed Student’s t-test. The statistical
signiﬁcance level was set at p < 0 05.
3. Results
The anthropometric parameters including the metabolic
parameters of T1DM patients at admission are presented in
Table 1.
Results presented on Figure 1(a) show a signiﬁcant
decrease (by 67%; p < 0 001) of plasma CRP concentration
and plasma FFA concentration (by 46%; p < 0 001) after
exposure to HBOT (Figure 1(b)).
The serum nitrite/nitrate concentration (Figure 2(a)) was
decreased by 29% (before HBOT=100%; after HBOT=71
± 8.9%; p < 0 01), while serum arginase activity was increased
by 32% after exposure to HBOT (before HBOT=100%; after
HBOT=132± 15.1%; p < 0 05) (Figure 2(b)). To assess a
decrease in iNOS synthesis, protein samples from cell lysates
were analyzed by Western blotting (Figure 2(c)). HBOT
signiﬁcantly decreased the iNOS protein level (before
HBOT=1-fold; after HBOT=0.87± 0.05-fold, p < 0 01).
Since the promoter of iNOS gene is the binding site for
NFκB transcription factor [21], we further examined whether
NFκB is involved in HBOT downregulation of iNOS activi-
ty/expression by measuring p65 subunit level of NFκB
(Figure 3). Furthermore, we also assessed the eﬀect of HBOT
of the phosphorylation state of NFκB-p65 at Ser536 by the
immunoblotting with the phospho-speciﬁc NFκB-p65 anti-
body that recognizes NFκB-p65 only when phosphorylated
at Ser536.
HBOT leads to a signiﬁcant decrease of the level of the
total form of NFκB-p65 by 0.23-fold (before HBOT=1-fold;
after HBOT=0.77± 0.07-fold, p < 0 01) (Figure 3(a)), as well
as the level of the phosphorylated form of NFκB-p65 by
0.3-fold (before HBOT=1-fold; after HBOT=0.70±
0.13-fold, p < 0 05) (Figure 3(b)). However, HBOT increased
the ratio between the phosphorylated and total forms of
NFκB-p65 in the lysate of T1DM patients’ lymphocytes
(before HBOT=1-fold; after HBOT=1.42± 0.17-fold,
p < 0 05) (Figure 3(c)).
Table 1: Anthropometric and metabolic parameters of T1DM
patients. Results are presented as mean± SEM: HBOT: hyperbaric
oxygen therapy; T1DM: type 1 diabetes mellitus; BMI: body mass
index; HbA1c: glycosylated hemoglobin; WBC: white blood cells;
RBC: red blood cells; TG: triglyceride.
Parameter Mean± SE (min–max) Reference range
Age (years) 63± 2.1 (50–80)
Weight (kg) 82.6± 2.9 (62–99)
High (m) 1.74± 0.02 (1.6–1.8)
BMI (kg/m) 27.4± 0.9 (21.8–33.7)
HbA1c (%) 8.6± 0.08 (6.1–12.7) 4.8–5.9
Hemoglobin (g/L) 136± 3.4 (111–169) 120–175
Hematocrit (%) 40± 0.1 (30–50) 35–50
WBC (×103/L) 8.3± 0.5 (3.4–11.3) 3.5–10.5
RBC (×106/L) 4.7± 0.2 (3.9–6.6) 3.9–5.7
Platelets (×103/L) 264± 26.7 (127–393) 150–450
Cholesterol (mmol/L) 5± 0.4 (3.25–7.9) 5-6.2
TG (mmol/L) 2.3± 0.4 (0.7–4.0) 1.7–2.2
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Since we have previously shown that the stimulation of
iNOS also involves activation of ERK1/2 phosphorylation
[22] and activation of Akt phosphorylation [23], we next
examined whether ERK1/2 and Akt are involved in decreased
iNOS activity/expression after the exposure to HBOT. There-
fore, we assessed the eﬀect of HBOT of the phosphorylation
state of ERK1/2 (Figure 4) and Akt (Figure 5) by the immu-
noblotting with phospho-speciﬁc ERK1/2 and Akt antibodies
that recognize ERK1/2 and Akt only when ERK is phosphor-
ylated at Thr202/Tyr204 and Akt at Ser473, respectively.
HBOT decreased the total ERK1/2 protein level (before
HBOT=1-fold; after HBOT=0.89± 0.05-fold; p < 0 05)
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Figure 1: Eﬀects of HBOT on plasma CRP and FFA levels. (a) The plasma level of CRP; (b) the plasma level of FFA. Results are expressed as %
of the value obtained before HBOT and represent mean± SEM (n = 15); ∗∗∗p < 0 001. CRP: C-reactive protein; FFA: free fatty acid. Other
abbreviations are under Table 1.
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Figure 2: Changes in the serum nitrite/nitrate concentration, arginase activity, and iNOS protein level in lymphocytes after HBO exposure.
(a) The serum nitrite/nitrate concentration was expressed as a % before HBOT; (b) the serum arginase activity was expressed as a % before
HBOT; (c) level of iNOS protein in lymphocytes, normalized to β-actin and expressed as fold change before HBOT (arbitrary control set at 1).
Inset: representative Western blots (n = 11 – 13); ∗∗p < 0 01; ∗p < 0 05. iNOS: inducible nitric oxide synthase. Other abbreviations are under
Table 1.
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(Figure 4(a)) and total Akt protein level, normalized to
β-actin (before HBOT=1-fold; after HBOT=0.89±
0.04-fold; p < 0 05) (Figure 5(a)). Similarly, HBOT decreased
phosphorylation of ERK1/2 (Figures 4(b) and 4(c)) (before
HBOT=1-fold; after HBOT=0.79± 0.06-fold; p < 0 01) and
phosphorylation of Akt (Figures 5(b) and 5(c)) (before
HBOT=1-fold; after HBOT=0.57± 0.11-fold; p < 0 01).
These results suggest that exposure to HBOT signiﬁcantly
decreases iNOS activity/expression and indicate that
ERK1/2 and Akt are involved in HBOT-downregulated iNOS
activity/expression in T1DM patients.
4. Discussion
The principal ﬁndings of our study included the observation
that in T1DM patients, HBOT downregulates the iNOS acti-
vity/expression by decreasing phosphorylation of ERK1/2
and Akt followed by a decreased activation of NFκB. For this
study, we have used HBOT as a medical treatment for
T1DM patients with the developed peripheral arterial
disease, with the purpose to reduce inﬂammation and to
promote microcirculation.
Biochemical proﬁle of DM is commonly presented by
elevated levels of HbA1c, CRP, FFA, and NO which provide
an environment of oxidative stress and inﬂammation [24].
HbA1c is a reliable biomarker for the diagnosis and prognosis
of DM and correlates well with the risk of long-term diabetes
complications [25]. Results from our study show that the
level of HbA1c was 8.6± 0.08%, which indicates a higher risk
of DM-associated complications [26].
Elevated FFA,which is common in thediabetic population
[27], may trigger systemic inﬂammation and impair NO
bioavailability, leading to impaired endothelium-dependent
and insulin-mediated vasodilation [28]. Increase in FFA level
is associated with an increase in NO level and upregulation of
iNOSmRNA as well as the reduction of insulin output in cul-
tured prediabetic rat pancreatic islets [29]. Also, increased
plasma FFA levels are accompanied by increased expression
of several NFκB-dependent cytokines, leading to chronic
inﬂammatory processes [30]. In our study, we observed a sig-
niﬁcant decrease in FFA afterHBOT inT1DMpatients. These
results are consistent with data gained by Teshigawara et al.
[31]. Teshigawara et al. showed that FFA concentration was
signiﬁcantly decreased after HBOT, implying that HBOT
could have beneﬁcial eﬀects on lipid metabolism. Clinical
manifestation of inﬂammation is characterized by the increase
of acute-phase proteins, among which prominent place has
CRP [32, 33]. The level of CRP is a well-known marker of
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Figure 3: Phosphorylation of NFκB-p65 at Ser536 in lymphocytes after HBO exposure. (a) Level of t-NFκB-p65 protein in lymphocytes,
normalized to β-actin and expressed as fold change before HBOT (arbitrary control set at 1); (b) level of p-NFκB-p65 (Ser536) protein in
lymphocytes, normalized to β-actin and expressed as fold change before HBOT (arbitrary control set at 1); (c) ratio of
p-NFκB-p65/t-NFκB-p65 expressed as fold change before HBOT (arbitrary control set at 1). Inset: representative Western blots (n = 5 – 15);
∗∗p < 0 01; ∗p < 0 05; p-NFκB-p65: the phosphorylated form of p65 subunit of nuclear factor-κB; t-NFκB-p65: the total form p65 subunit of
nuclear factor-κB. Other abbreviations are under Table 1.
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inﬂammation [32], and it is reported that CRP may stimulate
iNOS expression and NO production [34]. Our results show
that exposure to HBOT signiﬁcantly reduces the level of CRP
in T1DM patients. Thus, the results from our study suggest
that HBOT leads to a reduction of inﬂammation and subse-
quent progression of atherosclerosis [35]. iNOS is an impor-
tant mediator of inﬂammation and may be the critical link
between metabolic disorders and inﬂammation [36].
iNOS expression occurs after induction as a response to
cytokines and other proinﬂammatory agents. After induc-
tion, iNOS continuously produces 100- to 1000-fold more
NO than constitutive NOS [37, 38]. Excessive NO produc-
tion favors the formation of peroxynitrite and thus contrib-
utes to tissue injury and reduced NO bioavailability
[39, 40]. In our study, we have observed that HBOT leads
to a decrease in iNOS expression in lymphocytes and
consequently decreases the level of the serum nitrite/nitrate
concentration. Our results also show that HBOT increased
serum arginase activity, and increased arginase activity may
reduce the substrate availability of NOS, since NOS and argi-
nase use the same substrate, the amino acid L-arginine, and
consequently could reduce nitrite/nitrate concentration [41].
Moreover, numerous literature data reported that activi-
ties of iNOS and arginase are regulated reciprocally by cyto-
kines and that the inhibition of iNOS leads to the subsequent
decrease in the NO production that is associated with
increased arginase activity [42–44]. Elevated levels of glucose
in diabetes may enhance NO production through increased
expression of endothelial NOS (eNOS) and iNOS gene and
protein levels [8, 45–47]. Although iNOS/eNOS might be
responsible for the release of NO from endothelial cells
[47], numerous literature data reported that hyperglycaemia
increased the NO level mostly through activation of iNOS
[6, 48–50]. Thus, the decreased serum nitrite/nitrate con-
centration suggests that decreased iNOS and increased
arginase activity after exposure to HBOT in our study
may be due to decreased iNOS expression. This is in
accordance with other results [51–56]. Pedoto et al. have
also observed in their study that HBO pretreatment
reduces lipopolysaccharide-induced iNOS expression [51].
Also, HBOT reduces the level of exhaled NO for 1 h in
human subjects [55]. Similarly, rats exposed to HBOT for 7
days show signiﬁcantly decreased NOS activity [13], while
rabbits exposed to HBOT for 5 days have decreased expres-
sion of iNOS [52].
The results from our study reveal that HBOT signiﬁ-
cantly increased phosphorylation of NFκB-p65 at Ser536,
while it decreased the level of NFκB-p65 protein in lympho-
cytes of T1DM patients. Our results are in agreement with
the results of Meng et al. who have demonstrated that
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Figure 4: Phosphorylation of ERK1/2 at Thr202 and Tyr204 in lymphocytes after HBO exposure. (a) Level of t-ERK1/2 protein in lymphocytes,
normalized to β-actin and expressed as fold change before HBOT (arbitrary control set at 1); (b) level of p-ERK1/2/(Thr202/Tyr204) protein in
lymphocytes, normalized to β-actin and expressed as fold change before HBOT (arbitrary control set at 1); (c) ratio of p-ERK1/2/t-ERK1/2
expressed as fold change before HBOT (arbitrary control set at 1). Inset: representative Western blots (n = 14); ∗∗p < 0 01; ∗p < 0 05;
p-ERK1/2: the phosphorylated form of extracellular signal-regulated kinases 1 and 2; t-ERK1/2: the total form of extracellular
signal-regulated kinases 1 and 2. Other abbreviations are under Table 1.
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exposure of rats to HBO signiﬁcantly reduces the activation
of the NFκB protein [57]. Mattioli et al. reported that phos-
phorylation of NFκB-p65 at Ser536 negatively regulates the
import of NFκB-p65 to the nucleus [58]. Additionally, phos-
phorylation of NFκB-p65 at Ser536 plays an important role in
promoting the proteasomal degradation of NFκB-p65, thus
leading to transcriptional termination of NFκB-dependent
genes [59], and phosphorylation of NFκB-p65 at Ser536 regu-
lates the ability of nuclear IκBα to inhibit the NFκB binding
to promoters in human leukocytes and thereby inhibit tran-
scription of genes in a selective manner [60]. Furthermore,
phosphorylation of NFκB-p65 at Ser536 increases turnover
of NFκB-p65, thereby inhibiting NFκB activity in macro-
phages and subsequently reducing inﬂammation [61]. Since
iNOS expression is regulated primarily by control of gene
transcription, a possible explanation for the decrease of iNOS
protein level after HBOT may be that decreased activation of
transcription factor NFκB-p65 subunit, which has a binding
site on the iNOS gene promoter, consequentially leads to
reduced iNOS expression. Here, we demonstrate that HBOT
causes downregulation of NFκB-p65 protein and this
decrease could be because of the decreased cytokine level
after exposure to HBO [62]. Thus, we assume that HBOT
downregulates iNOS activity/expression by a mechanism
involving NFκB in combination with decreased CRP
concentrations. Although CRP by itself did not aﬀect NO
synthesis, CRP further enhanced cytokine-evoked increases
in iNOS mRNA protein levels [34]. Also, we postulate that
decreased iNOS expression is associated with decreased
expression of FFA translocase, a cluster of diﬀerentiation 36
(CD36), and a reduction in the level of FFA after exposure
to HBOT.
ERK1/2 is involved in the regulation of iNOS activa-
tion [63–66]. Increased ERK1/2 phosphorylation upregu-
lates both NFκB activity and iNOS protein expression
[64, 67–70], while inhibition of ERK1/2 phosphorylation
downregulates the expression of cytokine-induced NFκB-
activation [71]. Furthermore, inhibition of ERK1/2 decreases
iNOS gene expression [71]. In our study, HBOT signiﬁcantly
decreases the phosphorylation of ERK 1/2, and this decrease
could be due to the decreased NFκB activity [9]. Our results
are in accordance with the study of Niu et al. [72]. Niu
et al. reported that HBO suppressed the phosphorylation
of ERK1/2 and decreased the synthesis of NO. Therefore,
we assume that decreases in ERK1/2 phosphorylation
after exposure to HBOT could lead to the reduction of
NFκB activation and consequentially reduced expression of
iNOS protein.
Akt is an upstream activator of NFκB, whereby phos-
phorylated Akt (or ERK1/2) activates NFκB inhibitor kinase
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Figure 5: Phosphorylation of Akt at Ser473 in lymphocytes after HBO exposure. (a) Level of t-Akt protein in lymphocytes, normalized to
β-actin and expressed as fold change before HBOT (arbitrary control set at 1); (b) level of p-Akt (Ser473) protein in lymphocytes,
expressed as fold change before HBOT (arbitrary control set at 1); (c) ratio of p-Akt/t-Akt expressed as fold change before HBOT
(arbitrary control set at 1). Inset: representative Western blots (n = 7); ∗∗p < 0 01; ∗p < 0 05; p-Akt: the phosphorylated form of protein
kinase B; t-Akt: the total form of protein kinase B. Other abbreviations are under Table 1.
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and consequently leads to transcription and translation of
iNOS [68, 73]. Hattori et al. reported that the activation of
NFκB is suppressed by inhibitors of Akt [74]. In our study,
HBOT decreased Akt phosphorylation, indicating that acti-
vation of Akt is involved in mediating the eﬀect of HBOT
on the regulation of iNOS. Our results are in accordance with
the study of Felderhoﬀ-Mueser et al. who reported that
hyperoxia reduces phosphorylation of Akt at Ser473 [75].
Since the phosphorylation of Akt is necessary for NFκB acti-
vation, we suggest that a decrease in Akt phosphorylation
leads to NFκB downregulation and a decrease in iNOS
protein expression.
To explain our results, we proposed the following model
(Figure 6). Altered level of FFA, CRP, and cytokines caused
by T1DM induces inﬂammation which inﬂuences the
iNOS/NO pathway and thus promotes vascular complica-
tions by attenuating insulin action. This is likely a conse-
quence of increased ERK1/2/Akt activation, which further
upregulates NFκB. There are several possibilities to explain
the eﬀect of HBOT in the modulation of iNOS. It is possible
that HBOT leads to the decreased level of CRP, FFA, and
cytokines, and consequently this leads to decreased activa-
tion of ERK1/2 and Akt activation and thus decreases the
activity of NFκB, and subsequently iNOS or NFκB activa-
tion by cytokines in T1DM is achieved only through Akt.
Also, NFκB-p65 activation could be involved in ERK1/2
activation [9].
In accordance to the promising results of this study that
pointed out the early eﬀects of HBOT on some molecular
aspects of inﬂammation in T1DM patients, we are planning
to carry out another study that will be performed on a more
signiﬁcant sample size with inclusion of patients suﬀering
from metabolic syndrome and type 2 DM as well healthy
control subjects. The currently presented prospective pilot
study is based on the number of administered HBOT sessions
included in one HBOT course and the exploration of some
early inﬂammatory molecular eﬀects of HBOT after one
course of exposure. As the positive eﬀects are detected in
our study, the evaluation of long-term HBOT eﬀects
(e.g., after 1 or 5 years) regarding the molecular basis of the
anti-inﬂammatory eﬀects of the therapy is needed. Further-
more, there is a possibility to test the eﬀects of diﬀerent
HBOT administration protocols and to select the most
appropriate model (i.e., study plan could be performed either
through the increase in the number of sessions involved in
HBOT course or by shortening of the period between succes-
sive HBOT courses). Besides evaluating the molecular
mechanisms involved in the reduction of inﬂammation, it is
also necessary to design prediction models for major cardio-
and cerebrovascular atherosclerotic events and to examine
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Figure 6: The proposed mechanism by which HBOT aﬀects regulation of iNOS activity/expression and nitrite/nitrate production in T1DM
patients. iNOS: inducible nitric oxide synthase; NFκB-p65: the p65 subunit of nuclear factor-κB; NO: nitric oxide; ERK1/2: extracellular
signal-regulated kinases 1 and 2; Akt: protein kinase B; CRP: C-reactive protein; FFA: free fatty acid. Other abbreviations are under Table 1.
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the inﬂuence of various confounding variables that will be of
great interest and contribution in the planning of primary
and secondary prevention of major atherosclerotic accidents
in diabetic patients and in improving patients’ quality of life.
The limitation of our study is a small number of T1DM
patients exposed to HBOT. The other limitation of our study
is that we did not directly measure the level of cytokines and
we did not measure the level of NO in lymphocytes and the
level of NFκB in the lymphocyte nucleus.
In conclusion, in the present study, we demonstrate for
the ﬁrst time that HBOT causes downregulation of iNOS
activity/expression by a mechanism involving ERK1/2, Akt,
and NFκB, in T1DM patients. The results from our study
suggest that HBOT has a vital role in the reduction of inﬂam-
mation in T1DM patients. Future studies on a larger popula-
tion size are needed to elucidate the molecular mechanism by
which HBOT regulates iNOS activity/expression in T1DM
patients with vascular complications.
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